Individual generic drug information

octreotide

Reference monograph

Part of registered formulation

OCTREOTIDE ACETATE

Reference record: Octreotide
Source: BNF 80 (2020–2021)
Printed source pages: 1024, 1025
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Octreotide only.

Indications And Dose

Symptoms associated with carcinoid tumours with features of carcinoid syndrome,VIPomas, glucagonomas ▶BY SUBCUTANEOUS INJECTION ▶Adult: Initially 50 micrograms 1–2 times a day, adjusted according to response; increased to 200 micrograms 3 times a day, higher doses may be required exceptionally; maintenance doses are variable; in carcinoid tumours, discontinue after 1 week if no effect, if rapid response required, initial dose may be given by intravenous injection (with ECG monitoring and after dilution) Acromegaly, short-term treatment before pituitary surgery or long-term treatment in those inadequately controlled by other treatment or until radiotherapy becomes fully effective ▶BY SUBCUTANEOUS INJECTION ▶Adult: 100–200 micrograms 3 times a day, discontinue if no improvement within 3 months Prevention of complications following pancreatic surgery ▶BY SUBCUTANEOUS INJECTION ▶Adult: (consult product literature) Test dose before use of depot preparation ▶BY SUBCUTANEOUS INJECTION ▶Adult: Test dose 50–100 micrograms for 1 dose, test dose should be given if subcutanous octreotide not previously given Acromegaly | Neuroendocrine (particularly carcinoid) tumour adequately controlled by subcutaneous octreotide ▶BY DEEP INTRAMUSCULAR INJECTION USING DEPOT INJECTION ▶Adult: Initially 20 mg every 4 weeks for 3 months then adjusted according to response, increased if necessary up to 30 mg every 4 weeks, to be administered into the gluteal muscle, for acromegaly, start depot 1 day after the last dose of subcutaneous octreotide, for neuroendocrine tumours, continue subcutaneous octreotide for 2 weeks after ﬁrst dose of depot octreotide Advanced neuroendocrine tumours of the midgut, or tumours of unknown primary origin where non-midgut sites of origin have been excluded ▶BY DEEP INTRAMUSCULAR INJECTION USING DEPOT INJECTION ▶Adult: 30 mg every 4 weeks Reduce intestinal secretions in palliative care | Reduce vomiting due to bowel obstruction in palliative care ▶BY CONTINUOUS SUBCUTANEOUS INFUSION ▶Adult: 0.25–0.5 mg/24 hours (max. per dose 0.75 mg/24 hours), occasionally doses higher than the maximum are sometimes required

Source page 1024

Prescribing And Dispensing Information

Palliative care For further information on the use of octreotide in palliative care, see www.medicinescomplete. com/#/content/palliative/octreotide.

Source page 1024

National Funding Access Decisions

All Wales Medicines Strategy Group (AWMSG) decisions AWMSG No. 3732 The All Wales Medicines Strategy Group has advised (September 2018) that octreotide (Sandostatin ® LAR ®) is recommended as an option for use within NHS Wales for the treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.

Source page 1024

Safety

Extracted information for Octreotide only.

Interactions

→Appendix 1: octreotide

Source page 1024

Side Effects

▶Common or very common Arrhythmias. biliary sludge. dyspnoea. hyperbilirubinaemia. hypothyroidism. skin reactions. thyroid disorder ▶Uncommon Dehydration ▶Frequency not known Hepatic disorders. pancreatitis acute (after administration). thrombocytopenia SIDE-EFFECTS, FURTHER INFORMATION Administering non- depot injections of octreotide between meals and at bedtime may reduce gastrointestinal side-effects.

Source page 1024

Conception And Contraception

Effective contraception required during treatment.

Source page 1024

Pregnancy

Possible effect on fetal growth; manufacturer advises use only if potential beneﬁt outweighs risk.

Source page 1024

Breast Feeding

Manufacturer advises avoid—present in milk in animal studies.

Source page 1024

Hepatic Impairment

Manufacturer advises caution (risk of increased half-life in cirrhosis). Dose adjustments Manufacturer advises consider dose reduction—consult product literature.

Source page 1024

Monitoring Requirements

▶Monitor thyroid function on long-term therapy. ▶Monitor liver function. ▶With intravenous use ECG monitoring required with intravenous administration.

Source page 1024

Dose and formulations

Extracted information for Octreotide only.

Directions For Administration

For intravenous injection or intravenous infusion, dilute with Sodium Chloride 0.9% to a concentration of 10–50%.

Source page 1024

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Octreotide (Non-proprietary) Octreotide (as Octreotide acetate) 50 microgram per 1 ml Octreotide 50micrograms/1ml solution for injection pre-filled syringes | 5 pre-filled disposable injection P £18.85–£18.88 DT = £18.88 Octreotide 50micrograms/1ml solution for injection ampoules | 5 ampoule P £2.97–£18.60 DT = £14.87 Octreotide 50micrograms/1ml solution for injection vials | 5 vial P £22.00 Octreotide (as Octreotide acetate) 100 microgram per 1 ml Octreotide 100micrograms/1ml solution for injection ampoules | 5 ampoule P £32.65 DT = £27.97 Octreotide 100micrograms/1ml solution for injection pre-filled syringes | 5 pre-filled disposable injection P £30.33–£32.90 DT = £30.33 Octreotide 100micrograms/1ml solution for injection vials | 5 vial P £32.65 DT = £32.65 Octreotide (as Octreotide acetate) 200 microgram per 1 ml Octreotide 1mg/5ml solution for injection vials | 1 vial P £65.00 DT = £65.00 Octreotide (as Octreotide acetate) 500 microgram per 1 ml Octreotide 500micrograms/1ml solution for injection vials | 5 vial P £158.25 DT = £158.25 Octreotide 500micrograms/1ml solution for injection ampoules | 5 ampoule P £27.09–£169.35 DT = £135.47 Octreotide 500micrograms/1ml solution for injection pre-filled syringes | 5 pre-filled disposable injection P £154.22–£169.00 DT = £154.22 ▶Sandostatin (Novartis Pharmaceuticals UK Ltd) Octreotide (as Octreotide acetate) 50 microgram per 1 ml Sandostatin 50micrograms/1ml solution for injection ampoules | 5 ampoule P £14.87 DT = £14.87 Octreotide (as Octreotide acetate) 100 microgram per 1 ml Sandostatin 100micrograms/1ml solution for injection ampoules | 5 ampoule P £27.97 DT = £27.97 Octreotide (as Octreotide acetate) 500 microgram per 1 ml Sandostatin 500micrograms/1ml solution for injection ampoules | 5 ampoule P £135.47 DT = £135.47 Powder and solvent for suspension for injection ▶Olatuton (Teva UK Ltd) Octreotide (as Octreotide acetate) 10 mg Olatuton 10mg powder and solvent for prolonged-release suspension for injection vials | 1 vial P £494.74 DT = £549.71 Octreotide (as Octreotide acetate) 20 mg Olatuton 20mg powder and solvent for prolonged-release suspension for injection vials | 1 vial P £719.40 DT = £799.33 Octreotide (as Octreotide acetate) 30 mg Olatuton 30mg powder and solvent for prolonged-release suspension for injection vials | 1 vial P £898.57 DT = £998.41 ▶Sandostatin LAR (Novartis Pharmaceuticals UK Ltd) Octreotide (as Octreotide acetate) 10 mg Sandostatin LAR 10mg powder and solvent for suspension for injection vials | 1 vial P £549.71 DT = £549.71 Octreotide (as Octreotide acetate) 20 mg Sandostatin LAR 20mg powder and solvent for suspension for injection vials | 1 vial P £799.33 DT = £799.33 Octreotide (as Octreotide acetate) 30 mg Sandostatin LAR 30mg powder and solvent for suspension for injection vials | 1 vial P £998.41 DT = £998.41 eiiii F 1001

Source pages 1024, 1025

Clinical care

Extracted information for Octreotide only.

Treatment Cessation

Avoid abrupt withdrawal of short- acting subcutaneous octreotide (associated with biliary colic and pancreatitis).

Source page 1024

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

Initially 50 micrograms 1–2 times a day,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

100–200 micrograms 3 times a day, discontinue

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

(consult product literature)

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

Test dose 50–100 micrograms for 1 dose, test

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

Initially 20 mg every 4 weeks for 3 months then

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

30 mg every 4 weeks

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

0.25–0.5 mg/24 hours (max. per dose

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

octreotide

Reference monograph

Part of registered formulation

OCTREOTIDE ACETATE

Reference record: Octreotide
Source: BNF 80 (2020–2021)
Printed source pages: 1024, 1025
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Octreotide only.

Indications And Dose

Source page 1024

Prescribing And Dispensing Information

Palliative care For further information on the use of octreotide in palliative care, see www.medicinescomplete. com/#/content/palliative/octreotide.

Source page 1024

National Funding Access Decisions

Source page 1024

Safety

Extracted information for Octreotide only.

Interactions

→Appendix 1: octreotide

Source page 1024

Side Effects

Source page 1024

Conception And Contraception

Effective contraception required during treatment.

Source page 1024

Pregnancy

Possible effect on fetal growth; manufacturer advises use only if potential beneﬁt outweighs risk.

Source page 1024

Breast Feeding

Manufacturer advises avoid—present in milk in animal studies.

Source page 1024

Hepatic Impairment

Manufacturer advises caution (risk of increased half-life in cirrhosis). Dose adjustments Manufacturer advises consider dose reduction—consult product literature.

Source page 1024

Monitoring Requirements

▶Monitor thyroid function on long-term therapy. ▶Monitor liver function. ▶With intravenous use ECG monitoring required with intravenous administration.

Source page 1024

Dose and formulations

Extracted information for Octreotide only.

Directions For Administration

For intravenous injection or intravenous infusion, dilute with Sodium Chloride 0.9% to a concentration of 10–50%.

Source page 1024

Medicinal Forms

Source pages 1024, 1025

Clinical care

Extracted information for Octreotide only.

Treatment Cessation

Avoid abrupt withdrawal of short- acting subcutaneous octreotide (associated with biliary colic and pancreatitis).

Source page 1024

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

Initially 50 micrograms 1–2 times a day,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

100–200 micrograms 3 times a day, discontinue

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

(consult product literature)

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

Test dose 50–100 micrograms for 1 dose, test

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

Initially 20 mg every 4 weeks for 3 months then

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

30 mg every 4 weeks

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Adults

First line only; read the complete Indications and dose section above.

0.25–0.5 mg/24 hours (max. per dose

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1024

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.